Compare EVG & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Eaton Vance Short Diversified Income Fund Eaton Vance Short Duration Diversified Income Fund of Beneficial Interest
Current Price
| Metric | EVG | AGEN |
|---|---|---|
| Founded | N/A | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 142.9M | 147.4M |
| IPO Year | 2004 | 1999 |
| Metric | EVG | AGEN |
|---|---|---|
| Price | $10.99 | $3.78 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 43.3K | ★ 1.1M |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $42,877,086.00 |
| Revenue This Year | N/A | $107.63 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $8.89 |
| Revenue Growth | N/A | ★ 89.95 |
| 52 Week Low | $10.40 | $2.71 |
| 52 Week High | $11.45 | $7.34 |
| Indicator | EVG | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 61.00 | 47.21 |
| Support Level | $10.90 | $3.72 |
| Resistance Level | $11.02 | $4.72 |
| Average True Range (ATR) | 0.12 | 0.29 |
| MACD | 0.02 | -0.06 |
| Stochastic Oscillator | 61.70 | 17.20 |
Eaton Vance Short Duration Diversified Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to provide a high level of current income with a secondary objective of seeking capital appreciation to the extent consistent with its primary goal. The portfolio of investments consists of business equipment and services, automotive, cable and satellite television, chemicals and plastics, food products, and other areas.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.